Heavy cannabis use, dependence and the brain : a clinical perspective Emese Kroon, Lauren Kuhns, Eva Hoch & Janna Cousijn Addictions, 2019, 1-12. doi : 10.1111/add.14776 ABSTRACT Aims : To summarize and evaluate our knowledge of the relationship between heavy cannabis use, cannabis use disorder (CUD) and the brain. Methods : Narrative review of relevant literature identified through existing systematic reviews, meta-analyses and a PubMed search. Epidemiology, clinical representations, potential causal mechanisms, assessments, treatment and prognosis are discussed. Results : Although causality is unclear, heavy and dependent cannabis use is consistently associated with a high prevalence of comorbid psychiatric disorders and learning and memory impairments that seem [...]
Lire la suiteRenseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes (Version PDF - 2,690 Ko) https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/renseignements-medecins/renseignements-destines-professionnels-sante-cannabis-cannabinoides.html Santé Canada Auteur : Hanan Abramovici Ph.D. Co-auteurs : Sophie-Anne Lamour, Ph.D. et George Mammen, Ph.D. Nous republions cet excellent document de Santé Canada, et surtout, le résumé des indications reconnues, et envisagées, du cannabis thérapeutique. Aperçu des énoncés récapitulatifs Les énoncés récapitulatifs suivants visent à résumer le contenu des sections 4.0 (Usages thérapeutiques possibles) et 7.0 (Effets indésirables) et leurs sous-sections respectives. Les énoncés récapitulatifs peuvent être également trouvés dans leurs sections et sous-sections respectives dans le corps même du document. Remarque: la plupart des études [...]
Lire la suiteAcute effects of delta-9-tetrahydrocannabinol (THC) on resting state brain function and their modulation by COMT genotype Matthijs G. Bossong, Hendrika H. van Hell, Chris D. Schubart, Wesley van Saane, Tabitha A. Iseger, Gerry Jager, Matthias J.P. van Osch, J. Martijn Jansma, René S. Kahn, Marco P. Boks, Nick F. Ramsey European Neuropsychopharmacology, 2019, 13, 56, 1–11 https://doi.org/10.1016/j.euroneuro.2019.03.010 Abstract Cannabis produces a broad range of acute, dose-dependent psychotropic effects. Only a limited number of neuroimaging studies have mapped these effects by examining the impact of cannabis on resting state brain neurophysiology. Moreover, how genetic variation influences the acute effects of cannabis on resting state brain function [...]
Lire la suiteThe Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review Albert Batalla, Hella Janssen, Shiral S. Gangadin and Matthijs G. Bossong Journal of Clinical Medicine, 2019, 8, 1058 doi : 10.3390/jcm8071058 Abstract : The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use disorders (SUDs). The non-psychoactive cannabinoid compound, cannabidiol (CBD) is a highly promising tool in the treatment of both disorders. Here we review human clinical studies that investigated the ecacy of CBD treatment for schizophrenia, substance use disorders, and their comorbidity. In particular, we examined [...]
Lire la suiteLe cannabis thérapeutique expérimenté 2 ans à partir de 2020 Par Public Sénat avec l'AFP Vendredi 12 juillet 2019 à 16:06 L’Agence du médicament a donné, jeudi, son accord à une expérimentation du cannabis thérapeutique. Sous l’impulsion d’Esther Benbassa, un débat sur la question avait eu lieu au mois de mai dans l’hémicycle. La sénatrice écologiste se réjouit de cette expérimentation mais regrette la « frilosité » du cadre. Fin 2018, l’Agence du médicament (ANSM) avait mandaté un comité d’experts (CSST) pour lui fournir un projet-cadre d’expérimentation du cannabis thérapeutique. Jeudi, l’ANSM a donc donné son feu vert aux conditions d’une expérimentation qui démarrera [...]
Lire la suiteA Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans Gerhard Nahler, Franjo Grotenhermen, Antonio Waldo Zuardi, and Jose´ A.S. Crippa3 Cannabis and Cannabinoid Research, 2017, 2, 1, 81-86 DOI: 10.1089/can.2017.0009 Abstract Cannabidiol (CBD), a major cannabinoid of hemp, does not bind to CB1 receptors and is therefore devoid of psychotomimetic properties. Under acidic conditions, CBD can be transformed to delta9 tetrahydro-cannabinol (THC) and other cannabinoids. It has been argued that this may occur also after oral administration in humans. However, the experimental conversion of CBD to THC and delta8-THC in simulated gastric fluid (SGF) is a highly artificial approach that deviates [...]
Lire la suiteThe Clinical Significance of Endocannabinoids in Endometriosis Pain Management Jerome Bouaziz, Alexandra Bar On, Daniel S. Seidman, and David Soriano Cannabis and Cannabinoid Research, 2017, 2, 1, 72-80 DOI : 10.1089/can.2016.0035 Abstract Introduction : Patients with endometriosis often suffer from diffuse and poorly localized severe pain. The current pain management strategies include medical and hormonal therapy, as well as surgery. Medical management of pain is often insufficient and is associated with high rate of recurrence. Better pain management is therefore of urgent need. Methods : Among the various candidates, the endocannabinoid system (ECS) has recently emerged as a relevant pharmacological target for themanagement of endometriosis-related pain. [...]
Lire la suiteRetrouvez l’ensemble des interventions des 24es Rencontres du RESPADD - GRECC : Utilisation cliniques des cannabinoïdes, juin 2019 Sarah LEJCZAK "Utilisation du Marinol en France : enquête auprès des prescripteurs" Roland TUBIANA et Fabienne CABY "Infection VIH et cannabinoïdes, état des lieux et pistes en recherche clinique" Allison McKIM : "Addicted to rehab : race, gender and drugs in the era of mass incarceration" Fabrice Olivet : "Races et drogues, les termes du sujet" François BAILLY : "Le cannabidiol en traitement "anti-addictif" chez les patients alcooliques : l'étude Caramel" Julien AZUAR "Usage de CBD et maladie psychiatrique" Pierre CHAMPY : "Cannabis sativa, plante médicinale en France ?" Jean-Michel [...]
Lire la suiteHow effective and safe is medical cannabis as a treatment of mental disorder ? A systematic review HOCH E., NIEMANN D., von KELLER R., SCHNEIDER M., FRIEMEL C.M., PREUSS U.W., HASAN A., POGARELL O. European Archives of Psychiatry and Clinical Neuroscience, 2019 https://doi.org/10.1007/s00406-019-00984-4 Abstract We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006—August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general social anxiety, posttraumatic stress disorder, anorexia nervosa, [...]
Lire la suiteThe diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids : D9-tetrahydrocannabinol, cannabidiol and D9-tetrahydrocannabivarin Roger G. Pertwee British Journal of Pharmacology, 2008, 153, 199–215 doi:10.1038/sj.bjp.0707442 Cannabis sativa is the source of a unique set of compounds known collectively as plant cannabinoids or phytocannabinoids. This review focuses on the manner with which three of these compounds, (-)-trans-D9-tetrahydrocannabinol (D9-THC), (-)- cannabidiol (CBD) and (-)-trans-D9-tetrahydrocannabivarin (D9-THCV), interact with cannabinoid CB1 and CB2 receptors. D9-THC, the main psychotropic constituent of cannabis, is a CB1 and CB2 receptor partial agonist and in line with classical pharmacology, the responses it elicits appear to be strongly influenced both by [...]
Lire la suite